



GREEN SKY LABS

# INVESTMENT OPPORTUNITY

BIOTECH AND RELATED INDUSTRIES

---

*Unique proprietary technologies in the biotech space position Green Sky Labs as a leader in next generation healthcare.*

# ABOUT GREEN SKY LABS INC.

## COMPANY OVERVIEW

Since its inception in 2014, Green Sky Labs Inc. ("GSL" or the "Company") has incubated disruptive technologies in the biotech industry. The companies which GSL is commercializing include those in artificial intelligence, machine learning, genetics, nutraceutical and pharmaceutical product development. To date, the Company has raised over \$55 million USD to fund the development and commercialization of its five business verticals, two of which have technologies that are being applied to the current COVID-19 pandemic. The leadership team at the parent and subsidiary levels has extensive experience in management, finance, entrepreneurship, pharma/nutraceutical and IT related industries.

## ADDITIONAL WARRANT OPTIONS

Investors will have warrants totaling the amount of the initial debenture investment. These warrants will extend to two years after the date of the investment and will be at priced at \$1.20, the same as the conversion price of the debenture. For example, if \$1.2M invested in GSL debenture then investor has right for two years to purchase up to one million shares of Green Sky Labs at \$1.20 per share (totaling \$1.2M).

Biotechnology Market Value  
Worth \$729 Billion by 2025.



## HIGHLIGHTS

- Clear and present growth opportunities
- Strong affiliates and strategic partnerships with well established sales channels
- Proprietary technologies
- Extraordinary scaling capacities

## INVESTMENT OPPORTUNITY

- \$7.5M USD Debenture 1yr, 12% interest, fully secured on all assets (after \$7.5M from prior notes)
- Investor has right to convert at \$1.20 per share
- Automatic conversion at \$1.20 when trading share price reaches \$2.00
- Additional warrant options in Green Sky Labs equal to initial investment

## ANTICIPATED USE OF FUNDS

- Working capital for parent company and all business lines
- Completion of construction of hemp processing facility
- Completion of all work required for initial public offering

For Accredited and Institutional Investors Only

## SUBSIDIARY AND AFFILIATE COMPANIES

### MY NEXT HEALTH

- GSL's AI division merged with a leading genetics research firm launching genomics-based insights and interventions.
- Commercializing for a number of diseases including COVID-19. In collaboration with IBM's AI machine learning platform, development of a proprietary case management system disease entities. Currently with a pipeline of enthusiastic indications of interest from major insurance carriers.

### AGENTIX CORP.

- Agentix leverages innovative drug delivery technologies in partnership with BIONOVA developing consumer product lines for broad dermatology and topical analgesics. Pharma therapies being targeted include CINV, LGDS and Onychomycosis. Publicly traded on the OTC Markets and preparing to uplist on a major US exchange.

### NECTAR HEALTH SCIENCES

- Nectar has developed advanced proprietary technology resulting in 99% pure cannabinoid isolates so precise to isolate at consistent commercial production. Protected by multiple World patent filings. Partnering with Fortune 100 company to scale and commercialize technology for global pharmaceutical industry.

### KALMEX, INC.

- Kalmex Inc., in a joint venture with world leading membrane technology company and investment group, Petro Sep, is producing, full spectrum CBG and CBD cannabinoid extracts and isolates through advanced non-solvent-based technology at a significant cost advantage. 25 Year exclusive global technology rights as partner.

### TRICHOME AGRONOMY CORP.

- Trichome's multistage agronomy program of creating high quality conditioned whole-plant hemp flower/biomass is one of the largest growers in Canada. Focused on optimizing whole-plant cultivation capable of adapting with the industry: hemp fiber, hurd, flowers for use in extract, & isolate production on an industrial scale.

The Cannabis Market is Projected to Grow at a CAGR of 30.7% to Reach USD 39.35 Billion by 2023.